Infusion Pumps — NCD 223 | CMS Coverage Update

TL;DR: The Centers for Medicare & Medicaid Services modified NCD 223 governing infusion pump coverage, with an effective date of March 7, 2026. Here's what billing teams need to know before submitting claims.

CMS infusion pump coverage policy under NCD 223 Medicare spans multiple indications — from insulin pumps for diabetes to chemotherapy pumps for liver cancer — and each one carries distinct medical necessity criteria. This update consolidates and clarifies those requirements. The policy covers both external and implantable infusion pumps, with tightly defined clinical thresholds that directly determine whether your claim pays or gets denied. No specific CPT or HCPCS codes are listed in this policy document, but the clinical criteria govern how your payer reviews claims tied to infusion pump billing across DME billing categories.

---

Quick-Reference Table

Field	Detail Copy
Payer	CMS (Centers for Medicare & Medicaid Services)
Policy	Infusion Pumps — NCD 223
Policy Code	NCD 223
Change Type	Modified
Effective Date	2026-03-07
Impact Level	High
Specialties Affected	Oncology, endocrinology, hematology, pain management, hospice, home health, DME suppliers
Key Action	Audit documentation for all active infusion pump patients against the updated medical necessity criteria before March 7, 2026

---

CMS Infusion Pump Coverage Criteria and Medical Necessity Requirements 2026

NCD 223 is the National Coverage Determination governing Medicare coverage of infusion pumps as durable medical equipment. It defines which clinical indications qualify, what documentation CMS requires, and where the coverage stops.

The coverage policy applies to devices that deliver parenteral drugs under pressure at a regulated flow rate. CMS draws a hard line between external pumps and implantable pumps — and between institutional settings and home settings. Your documentation needs to match that distinction exactly, or you're looking at a claim denial.

Continuous Subcutaneous Insulin Infusion (CSII) — The Most Complex Criteria

CSII pumps carry the most detailed medical necessity requirements in this policy. Patients must meet two layers of criteria: a C-peptide or autoantibody test, plus either Criterion A or Criterion B.

The C-Peptide / Autoantibody Requirement: Every CSII patient must be insulinopenic. CMS defines insulinopenia as a fasting C-peptide level at or below 110% of the lower limit of normal for the lab's measurement method. For patients with renal insufficiency and creatinine clearance at or below 50 ml/minute, a modified threshold applies — document the creatinine clearance calculation in the record. Alternatively, a patient who tests beta cell autoantibody positive satisfies this requirement in place of C-peptide testing.

Criterion A (New to Pump Therapy): The patient must have completed a comprehensive diabetes education program. They must have been on at least three insulin injections per day for at least six months before pump initiation. They must have documented glucose self-testing averaging at least four times per day in the two months before pump start. And they must meet at least one of these clinical markers: HbA1c above 7.0%, recurring hypoglycemia, wide pre-meal glucose fluctuations, dawn phenomenon with fasting blood sugars frequently over 200 mg/dl, or a history of severe glycemic excursions.

That's five conditions stacked together. Every one of them needs to be in the chart before you bill.

Criterion B (Pre-Medicare Pump Users): If the patient was already on a pump before Medicare enrollment, they qualify under Criterion B — provided they have documented glucose self-testing averaging at least four times per day in the month before enrollment. This is a narrower documentation requirement, but it still needs to be explicit in the record.

Ongoing CSII Requirements: Coverage for CSII doesn't end at initiation. CMS requires that the patient's treating physician continues to manage the insulin therapy. The physician — not a non-physician practitioner — must provide this ongoing management. The patient also needs to be seen by the treating physician at least every three months. If your practice uses NPPs for diabetes follow-up, check your documentation structure now. If visits are not attributed to the treating physician, you may have a prior authorization or recertification problem waiting to surface.

External Pump Indications — Cleaner Criteria, Still Specific

For indications outside of CSII, the medical necessity criteria are more straightforward, but each one has strings attached.

Iron Poisoning: External pumps are covered for administering deferoxamine in acute iron poisoning and iron overload. Coverage has been in place since September 26, 1984. The clinical indication needs to match — this isn't a catch-all for any iron-related condition.

Thromboembolic Disease: External pumps used in an institutional setting are covered for heparin administration in thromboembolic disease and pulmonary embolism. The institutional setting requirement is hard. Home use for this indication does not qualify under this coverage policy.

Liver Cancer Chemotherapy: The external chemotherapy infusion pump is covered for primary hepatocellular carcinoma or colorectal cancer when the disease is unresectable, or when the patient refuses surgical excision. Document the unresectability determination or the patient's refusal explicitly. Without that, you have no coverage hook.

Morphine for Intractable Cancer Pain: External pumps for morphine infusion in intractable cancer pain are covered in any setting — inpatient, outpatient, or hospice. This is one of the more flexible coverage allowances in the policy, but "intractable pain caused by cancer" still needs to be documented as the clinical basis.

---

CMS Infusion Pump Exclusions and Non-Covered Indications

CMS does not cover CSII pumps for patients who don't meet the C-peptide or autoantibody criteria — even if the patient has type 1 diabetes and has been on insulin for years. The lab result has to be in the record.

External heparin pumps for home use — not in an institutional setting — are not covered under the thromboembolic disease indication. This is a common billing error. Patients discharged home on heparin via an external pump do not qualify under this policy.

Implantable pump coverage carries its own criteria set. The policy covers implantable pumps for specific indications including severe spasticity, hepatic arterial infusion for liver tumors, and morphine for chronic intractable pain in non-malignant conditions — but these come with separate documentation and prior authorization requirements. If you bill implantable pumps, review the full NCD 223 document for those criteria in detail.

---

Coverage Indications at a Glance

---

CMS Infusion Pump Billing Guidelines and Action Items 2026

The effective date of March 7, 2026 is your deadline. Claims for services on or after that date will be reviewed against the updated criteria. Here's what to do before then.

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Infusion Pumps Under NCD 223

The policy document for NCD 223 does not list specific CPT, HCPCS, or ICD-10 codes. This is not unusual for a National Coverage Determination — the NCD defines clinical criteria, and code-level guidance typically comes from your MAC's LCD or the associated billing article.

For infusion pump billing, your billing team should work with your MAC's billing article tied to NCD 223 to identify the applicable HCPCS codes for external pumps, implantable pumps, and CSII devices. These typically fall in the E-code range for durable medical equipment. Do not assume a code is covered simply because the clinical indication qualifies — the code must also be on the covered list in your MAC's billing article.

If your MAC has published a related LCD, pull it alongside NCD 223. The LCD will specify the covered HCPCS codes and the ICD-10-CM diagnosis codes that support medical necessity. Billing without that cross-reference is where most infusion pump claim denial issues start.

---